A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Brief description of study

The main goal of this phase III study is to evaluate whether adjuvant therapy with crizotinib (an ATP blocker of several tyrosine kinases) will result in improved overall survival compared to placebo in people with Anaplastic Lymphoma Kinase-positive non-small cell lung cancer.  Also, we will evaluate how well crizotinib is tolerated in your body.


Clinical Study Identifier: s16-02072
ClinicalTrials.gov Identifier: NCT02201992
Principal Investigator: Elaine Shum.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.